AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8026290
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (crossed over to polymeric dressing)
Trial: 2531184
Drug: Cilazapril (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilazapril (2.5 mg daily)
Trial: 3310586
Drug: Propranolol (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (120 mg daily)
Trial: 4564559
Drug: ADV‐21 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADV‐21 vaccine (10^6.4 TCID(50))
Trial: 4564559
Drug: ADV‐21 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADV‐21 vaccine (10^6.8 TCID(50))
Trial: 4564559
Drug: ADV‐21 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADV‐21 vaccine (10^4.6 TCID(50))
Trial: 4564559
Drug: ADV‐21 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADV‐21 vaccine (10^2.4 TCID(50))
Trial: 24115184
Drug: Calcium 2000
RxNorm normalized name: calcium gluconate
DrugBank: Calcium gluconate (DB11126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium 2000 mg/d
Trial: 24115184
Drug: Calcium 2000
RxNorm normalized name: calcium gluconate
DrugBank: Calcium gluconate (DB11126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium 2000 mg/d and Vitamin D3 800 IU/d
Trial: 19537528
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation (generic alternative)
Trial: 19537528
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation (standard preparation)
Trial: 16740440
Drug: Daily supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily supplementation (DS) - 60 mg iron, 200 mcg folic acid, 1 mcg vitamin B12 daily
Trial: 16740440
Drug: Weekly supplementation
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly supplementation (WS) - two tablets once weekly
Trial: 9547830
Drug: Other factors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other factors (e.g., heredity, social class, maternal age, etc.)
Trial: 29133549
Drug: RG7667 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RG7667 (10 mg/kg of each antibody, 4 doses at transplant, 1, 4, and 8 weeks)
Trial: 22299818
Drug: Transcranial laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcranial laser therapy (TLT)
Trial: 21367352
Drug: Eszopiclone 3
RxNorm normalized name: eszopiclone 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eszopiclone 3 mg at bedtime
Trial: 18714238
Drug: Serial Concurrent
RxNorm normalized name: Echinacea, aerial parts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serial Concurrent Exercise (CE)
Trial: 18714238
Drug: Integrated Concurrent
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrated Concurrent Exercise (CE)
Trial: 12882067
Drug: Gastric insufflation
RxNorm normalized name: gastric mucins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gastric insufflation of 350 mL of air
Trial: 10837440
Drug: Cefdinir 300
RxNorm normalized name: cefdinir 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefdinir 300 mg bd for 5 days
Trial: 10837440
Drug: Cefprozil 500
RxNorm normalized name: cefprozil 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefprozil 500 mg bd for 10 days
Trial: 10203402
Drug: 5 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g MgSO4
Trial: 3011885
Drug: ACTH 1‐17
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACTH 1‐17 (random infusion)
Trial: 3011885
Drug: Saline (random
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline (random infusion)
Trial: 24507091
Drug: Rifampicin 300
RxNorm normalized name: Rifampicin 300 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampicin 300 mg twice daily
Trial: 24507091
Drug: Placebo (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (50 mg riboflavin capsules)
Trial: 23648372
Drug: Cannabis (115
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cannabis (115 mg Δ9-THC, twice daily)
Trial: 16610922
Drug: Oxycodone-acetaminophen
RxNorm normalized name: acetaminophen / oxycodone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone-acetaminophen
Trial: 11712308
Drug: Amilorid (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amilorid (10 mg)
Trial: 11712308
Drug: Lithium carbonate
RxNorm normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lithium carbonate (500 mg)
Trial: 7874096
Drug: Amantadine 100
RxNorm normalized name: amantadine 100 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amantadine 100 mg three times daily
Trial: 1451725
Drug: MK-571 (L-660,711)
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-571 (L-660,711) administered intravenously, single doses up to 1500 mg
Trial: 1451725
Drug: MK-571 (L-660,711)
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-571 (L-660,711) administered orally, multiple doses of 100, 300, and 600 mg t.i.d. for 31 doses
Trial: 6837255
Drug: 20 ml
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 ml mepivacaine with adrenaline
Trial: 6837255
Drug: 40 ml
RxNorm normalized name: hydrogen peroxide 40 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 ml mepivacaine with adrenaline
Trial: 6837255
Drug: 80 ml
RxNorm normalized name: urinary bag 480 mL MISCELL EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 ml mepivacaine with adrenaline
Trial: 6837255
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (20 ml, 40 ml, 80 ml)
Trial: 29451912
Drug: Adjuvant imatinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant imatinib treatment for one or three years
Trial: 26994121
Drug: Thienopyridine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thienopyridine plus aspirin (after 12 months)
Trial: 10195381
Drug: Metformin (MET)
RxNorm normalized name: metformin / pioglitazone Oral Tablet [Actoplus Met]
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin (MET) 500 mg twice daily
Trial: 10195381
Drug: Dexfenfluramine (DEX)
RxNorm normalized name: dexfenfluramine
DrugBank: Dexfenfluramine (DB01191)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexfenfluramine (DEX) 15 mg thrice daily
Trial: 2317464
Drug: Intravenous phenytoin
RxNorm normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous phenytoin sodium
Trial: 7364321
Drug: Oral prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral prednisone (0.3 mg per kg)
Trial: 7364321
Drug: Oral prednisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisolone (0.3 mg per kg)
Trial: 29558241
Drug: Prism adaptation
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prism adaptation treatment for 10 days
Trial: 31068272
Drug: Dolutegravir 50
RxNorm normalized name: dolutegravir 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dolutegravir 50 mg with co-formulated emtricitabine 200 mg and tenofovir alafenamide 25 mg
Trial: 21861419
Drug: Intravenous fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous fentanyl (0.5 microg x kg(‐1) x hr(‐1))
Trial: 21861419
Drug: Intravenous dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous dexmedetomidine (0.4‐0.7 microg x kg(‐1) x hr(‐1) decreased to 0.2‐0.7 microg x kg(‐1) x hr(‐1))
Trial: 21861419
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no continuous intravenous analgesia)
Trial: 19623196
Drug: Psyllium treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psyllium treatment for 2 months
Trial: 319120
Drug: Nomifensin, 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nomifensin, 75 mg/day
Trial: 319120
Drug: Viloxazine, 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Viloxazine, 150 mg/day
Trial: 31308269
Drug: Ridge augmentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ridge augmentation using non‐resorbable ePTFE membrane only
Trial: 31308269
Drug: Ridge augmentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ridge augmentation using ePTFE and tenting screw with bone graft Bio‐Oss mixed with autogenous bone particles
Trial: 31308269
Drug: Ridge augmentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ridge augmentation with a bone block
Trial: 28450193
Drug: Daily deflazacort
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily deflazacort
Trial: 24898537
Drug: Odanacatib 50mg
RxNorm normalized name: Odanacatib
DrugBank: Odanacatib (DB06670)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Odanacatib 50mg weekly (ODN)
Trial: 22036245
Drug: Glimepiride/metformin 1/500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glimepiride/metformin 1/500 mg SR
Trial: 22036245
Drug: Glimepiride/metformin 2/500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glimepiride/metformin 2/500 mg SR
Trial: 16425133
Drug: Treatment of
RxNorm normalized name: DRUGS FOR TREATMENT OF LEPRA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of H. pylori infection plus iron supplementation for 6 weeks
Trial: 12868803
Drug: Docetaxel (substituted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel (substituted for fluorouracil in combination with doxorubicin and cyclophosphamide)
Trial: 1471549
Drug: Non-effervescent Antabuse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-effervescent Antabuse tablets (400 mg DSF after overnight fast)
Trial: 1471549
Drug: Effervescent Antabuse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Effervescent Antabuse tablets (800 mg DSF after a light standardized meal)
Trial: 24205185
Drug: MVA.HIVA vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MVA.HIVA vaccine
Trial: 22300892
Drug: Continuous subcutaneous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous subcutaneous administration of 12 million units (MU) IFN‐α2b daily with ribavirin (1,000‐1,600 mg) for 48 weeks
Trial: 22300892
Drug: Continuous subcutaneous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous subcutaneous administration of 9 MU IFN‐α2b daily with ribavirin (1,000‐1,600 mg) for 48 weeks
Trial: 22300892
Drug: Continuous subcutaneous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous subcutaneous administration of 6 MU IFN‐α2b daily with ribavirin (1,000‐1,600 mg) for 48 weeks
Trial: 22300892
Drug: Continuous subcutaneous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous subcutaneous administration of IFN‐α2b with ribavirin
Trial: 22300892
Drug: Continuous subcutaneous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous subcutaneous administration of IFN‐α2b
Trial: 16011678
Drug: Maximum likelihood
RxNorm normalized name: Maximum-H
DrugBank: Hydrocortisone (DB00741)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Maximum likelihood estimator (MLE) for treatment assignment
Trial: 16011678
Drug: Data from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Data from a trial comparing two antipsychotics
Trial: 7573997
Drug: Ephedrine infusion
RxNorm normalized name: Ephedrine
DrugBank: Ephedrine (DB01364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ephedrine infusion to increase systolic blood pressure by 20%
Trial: 1659173
Drug: Radiation Therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation Therapy (RT) only
Trial: 1659173
Drug: Radiation Therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation Therapy + Chemotherapy (RT + Chemo)
Trial: 1659173
Drug: Radiation Therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation Therapy + Chemotherapy + Misonidazole (RT + Chemo/Miso)
Trial: 28783867
Drug: Intravaginal ring
RxNorm normalized name: taurolidine
DrugBank: Taurolidine (DB12473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravaginal ring (IVR) releasing 1050 μg ATZ per day and 40 μg LNG per day with 400 mg miconazole administered on 3 consecutive evenings during treatment on days 9-11.
Trial: 28783867
Drug: Intravaginal ring
RxNorm normalized name: taurolidine
DrugBank: Taurolidine (DB12473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravaginal ring (IVR) releasing 1050 μg ATZ per day and 40 μg LNG per day with 100 mg clindamycin administered on 3 consecutive evenings during treatment on days 9-11.
Trial: 28783867
Drug: Intravaginal ring
RxNorm normalized name: taurolidine
DrugBank: Taurolidine (DB12473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravaginal ring (IVR) releasing 1050 μg ATZ per day and 40 μg LNG per day with 75 mg nonoxynol-9 administered on 3 consecutive evenings during treatment on days 9-11.
Trial: 28783867
Drug: Intravaginal ring
RxNorm normalized name: taurolidine
DrugBank: Taurolidine (DB12473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravaginal ring (IVR) releasing 1050 μg ATZ per day and 40 μg LNG per day with tampon co-usage performed on days 20-23.
Trial: 27314120
Drug: Fixed-on-2 (FO2)
RxNorm normalized name: Pyrrolid-2-one
DrugBank: Pyrrolidone (DB19152)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-on-2 (FO2) implants
Trial: 27314120
Drug: Fixed-on-3 (FO3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-on-3 (FO3) implants
Trial: 11993095
Drug: Factor AF2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Factor AF2 (500 mg i.v., given at days 0‐3, 7‐10 and 11‐14)
Trial: 7532708
Drug: Granulocyte-colony stimulating
RxNorm normalized name: Granulocyte colony-stimulating factor pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Granulocyte-colony stimulating factor, 10 micrograms/kg intravenously, administered within 24 hours of birth and at 24-hour intervals for a maximum of three doses if neutropenia persisted
Trial: 2214101
Drug: Coffee (275
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coffee (275 mg of caffeine)
Trial: 24098692
Drug: Contraceptive implant
RxNorm normalized name: Implanon Contraceptive Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contraceptive implant
Trial: 22340793
Drug: Negative-pressure therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Negative-pressure therapy from -19 kPa to -8 kPa, n = 10
Trial: 22340793
Drug: Negative-pressure therapy,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Negative-pressure therapy, n = 10
Trial: 15651517
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline 20 cc (placebo)
Trial: 10965244
Drug: 5.5-mm Acrysof
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5.5-mm Acrysof lens implants through 3.2-mm outer and 4-mm inner temporal clear corneal openings (stretch incision)
Trial: 10965244
Drug: 5.5-mm Acrysof
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5.5-mm Acrysof lens implants
Trial: 8986972
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of fentanyl (C)
Trial: 8986972
Drug: Bolus dosing
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus dosing of fentanyl (B)
Trial: 8986972
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of fentanyl (C) in phase 2
Trial: 8986972
Drug: Bolus dosing
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus dosing of fentanyl (B) in phase 2
Trial: 1618662
Drug: CT/RT (three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT/RT (three cycles of cis‐platinum and 5‐FU chemotherapy followed by postoperative radiotherapy)
Trial: 6208728
Drug: Anesthetic cream
RxNorm normalized name: DIBUCAINE/DIPERODON ANESTHETIC CREAM
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anesthetic cream with an eutectic mixture of 5% lidocaine and 5% prilocaine applied for 5-15 min.
Trial: 6208728
Drug: Anesthetic cream
RxNorm normalized name: DIBUCAINE/DIPERODON ANESTHETIC CREAM
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anesthetic cream with an eutectic mixture of 5% lidocaine and 5% prilocaine applied for 30-60 min.
Trial: 29624523
Drug: Weekly PP
RxNorm normalized name: propoxyphene hydrochloride Oral Capsule [PP-Cap]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly PP exercises
Trial: 17686672
Drug: Natural interferon
RxNorm normalized name: interferon beta natural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natural interferon treatment for further 16‐36 weeks (mean 23.7 weeks) after pegylated interferon + ribavirin treatment cessation.
Trial: 17686672
Drug: Pegylated interferon
RxNorm normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pegylated interferon + ribavirin treatment (before cessation).
Trial: 17686672
Drug: Natural interferon
RxNorm normalized name: interferon beta natural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natural interferon treatment.
Trial: 31796467
Drug: Novel screening
RxNorm normalized name: Novel influenza-H1N1-09
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel screening program for gastric cancer using serologic tests of Helicobacter pylori antibodies and pepsinogens, and positive family history of gastric cancer in first‐degree relatives (FDR).
Trial: 29284453
Drug: ST segment
RxNorm normalized name: ST-36
DrugBank: ST-36 (DB17275)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ST segment analysis (STan) monitoring as an adjunct to cardiotocography (CTG)
Trial: 26024297
Drug: Blueberry smoothie
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blueberry smoothie (twice daily for six weeks)
Trial: 26024297
Drug: Placebo smoothie
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo smoothie (twice daily for six weeks)
Trial: 15617954
Drug: Troglitazone 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Troglitazone 150 mg/d
Trial: 15617954
Drug: Troglitazone 300
RxNorm normalized name: troglitazone 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Troglitazone 300 mg/d
Trial: 9239526
Drug: Paclitaxel therapy
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel therapy at a dose of 175 mg/m2
Trial: 9239526
Drug: Pretreatment with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pretreatment with potentially neurotoxic drugs (cisplatin and carboplatin)
Trial: 8108224
Drug: HbOC-DTP combined
RxNorm normalized name: DTP-348
DrugBank: DTP-348 (DB12741)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HbOC-DTP combined vaccine
Trial: 8108224
Drug: Separate injections
RxNorm normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Separate injections of HbOC and DTP vaccines
Trial: 20014980
Drug: Intravenous iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron supplementation (ferric carboxymaltose)
Trial: 29538179
Drug: Oral iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral iron supplementation (ferrous sulfate)
Trial: 26428942
Drug: 4 courses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 courses of cisplatin 100 mg/mq and paclitaxel 175 mg/mq every 21 days (Group A)
Trial: 26428942
Drug: 6 courses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 courses of cisplatin 100 mg/mq and paclitaxel 175 mg/mq every 21 days (Group B)
Trial: 23229241
Drug: 1.23% NaF-gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.23% NaF-gel
Trial: 14662662
Drug: Artichoke extract
RxNorm normalized name: artichoke extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artichoke extract (3 capsules)
Trial: 14662662
Drug: Placebo (indistinguishable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (indistinguishable inert capsules)
Trial: 11058673
Drug: Levomethadyl acetate
RxNorm normalized name: Levomethadyl acetate
DrugBank: Levacetylmethadol (DB01227)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levomethadyl acetate (75 to 115 mg)
Trial: 11058673
Drug: Buprenorphine (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine (16 to 32 mg)
Trial: 11058673
Drug: High-dose methadone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose methadone (60 to 100 mg)
Trial: 11058673
Drug: Low-dose methadone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose methadone (20 mg)
Trial: 1621669
Drug: 10 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg ibuprofen therapy
Trial: 1621669
Drug: 15 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg/kg acetaminophen therapy
Trial: 1621669
Drug: 2.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg/kg ibuprofen therapy
Trial: 1621669
Drug: 5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/kg ibuprofen therapy